Conning Inc. Has $44.69 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Conning Inc. trimmed its position in Johnson & Johnson (NYSE:JNJGet Rating) by 11.9% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 252,320 shares of the company’s stock after selling 33,979 shares during the period. Conning Inc.’s holdings in Johnson & Johnson were worth $44,687,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Personal CFO Solutions LLC lifted its position in shares of Johnson & Johnson by 1.0% in the first quarter. Personal CFO Solutions LLC now owns 14,407 shares of the company’s stock worth $2,553,000 after purchasing an additional 149 shares in the last quarter. Lloyd Advisory Services LLC. lifted its position in shares of Johnson & Johnson by 2,021.4% in the first quarter. Lloyd Advisory Services LLC. now owns 891 shares of the company’s stock worth $158,000 after purchasing an additional 849 shares in the last quarter. MBL Wealth LLC purchased a new stake in shares of Johnson & Johnson in the first quarter worth approximately $983,000. CFO4Life Group LLC lifted its position in shares of Johnson & Johnson by 4.0% in the first quarter. CFO4Life Group LLC now owns 12,524 shares of the company’s stock worth $2,220,000 after purchasing an additional 484 shares in the last quarter. Finally, Spinnaker Trust lifted its position in shares of Johnson & Johnson by 1.4% in the first quarter. Spinnaker Trust now owns 47,615 shares of the company’s stock worth $8,439,000 after purchasing an additional 643 shares in the last quarter. 68.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In other news, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the sale, the chief accounting officer now owns 15,473 shares in the company, valued at $2,785,140. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now owns 71,311 shares in the company, valued at $12,336,803. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the sale, the chief accounting officer now owns 15,473 shares in the company, valued at approximately $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by corporate insiders.

Johnson & Johnson Trading Down 0.3 %

NYSE:JNJ opened at $173.20 on Thursday. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The firm has a market cap of $455.76 billion, a price-to-earnings ratio of 25.21, a P/E/G ratio of 3.28 and a beta of 0.63. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. The company’s 50 day moving average is $175.99 and its 200-day moving average is $174.36.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.02. The business had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. Johnson & Johnson’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the company posted $2.48 earnings per share. Equities analysts anticipate that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be paid a $1.13 dividend. The ex-dividend date is Monday, August 22nd. This represents a $4.52 annualized dividend and a dividend yield of 2.61%. Johnson & Johnson’s payout ratio is 65.79%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on JNJ shares. Wells Fargo & Company raised their price objective on shares of Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research report on Wednesday, July 13th. Raymond James raised their price objective on shares of Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a research report on Friday, July 8th. Finally, Daiwa Capital Markets initiated coverage on shares of Johnson & Johnson in a research report on Wednesday, June 22nd. They set an “outperform” rating on the stock. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $189.89.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.